MCID: OVR059
MIFTS: 54

Ovary Adenocarcinoma

Categories: Cancer diseases, Endocrine diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Ovary Adenocarcinoma

MalaCards integrated aliases for Ovary Adenocarcinoma:

Name: Ovary Adenocarcinoma 12 15
Ovarian Adenocarcinoma 12 59 6 17 72
Adenocarcinoma of the Ovary 12
Adenocarcinoma of Ovary 59
Ovarian Adenoacanthoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3713
NCIt 50 C7700
ICD10 via Orphanet 34 C56
UMLS via Orphanet 73 C0948216
Orphanet 59 ORPHA213504
UMLS 72 C0948216

Summaries for Ovary Adenocarcinoma

Disease Ontology : 12 An ovarian carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Ovary Adenocarcinoma, also known as ovarian adenocarcinoma, is related to ovarian mucinous adenocarcinoma and ovarian cystadenocarcinoma. An important gene associated with Ovary Adenocarcinoma is ERBB2 (Erb-B2 Receptor Tyrosine Kinase 2), and among its related pathways/superpathways are ERK Signaling and TGF-Beta Pathway. The drugs Oxaliplatin and Paclitaxel have been mentioned in the context of this disorder. Affiliated tissues include ovary, breast and testes, and related phenotypes are episodic abdominal pain and abdominal distention

Related Diseases for Ovary Adenocarcinoma

Diseases related to Ovary Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 337)
# Related Disease Score Top Affiliating Genes
1 ovarian mucinous adenocarcinoma 32.8 KRT7 KRT20 CDX2
2 ovarian cystadenocarcinoma 32.8 KRAS HRAS GNAS
3 serous cystadenocarcinoma 31.8 TP53 HRAS ERBB2
4 appendix adenocarcinoma 31.6 KRT7 KRT20 CDX2
5 clear cell adenocarcinoma 31.4 KRT7 KRT20 HNF1B ARID1A
6 teratoma 31.1 TP53 KRT7 CDX2
7 mucinous adenocarcinoma 30.9 MUC1 KRT7 KRT20 KRAS CDX2
8 ovarian serous cystadenocarcinoma 30.9 TP53 HRAS ERBB2 BAX
9 papillary serous adenocarcinoma 30.8 TP53 KRT7 KRT20 BRCA1
10 cystadenoma 30.8 MUC1 KRT7 KRT20
11 cystic teratoma 30.7 TP53 KRT7 KRT20 CDX2
12 papillary adenocarcinoma 30.7 TP53 MUC1 KRT7 ERBB2 CEACAM5
13 adenoma 30.7 TP53 KRAS GNAS CTNNB1
14 fallopian tube carcinoma 30.6 TP53 ERBB2 BRCA1
15 small cell carcinoma 30.6 TP53 KRT7 KRT20
16 embryonal sarcoma 30.5 TP53 SERPINA3 CTNNB1
17 mucinous cystadenocarcinoma 30.4 MUC1 KRT7 KRT20
18 testicular yolk sac tumor 30.4 SERPINA3 CEACAM5 CDX2
19 endocervical adenocarcinoma 30.4 TP53 KRT7 KRT20 CDX2
20 cystadenocarcinoma 30.3 TP53 MUC1 KRT7 HRAS ERBB2 CEACAM5
21 breast adenocarcinoma 30.3 TP53 KRAS ERBB2 C1RL BAX
22 papillary carcinoma 30.3 MUC1 KRT7 KRT20 ERBB2
23 adenocarcinoma 30.3 TP53 MUC1 KRAS HRAS GNAS ERBB2
24 ovarian clear cell carcinoma 30.2 TP53 KRT7 KRAS HNF1B ARID1A
25 bladder cancer 30.2 TP53 KRT20 KRAS HRAS ERBB2
26 tubular adenocarcinoma 30.1 MUC1 KRT20 ERBB2 CDX2
27 endometrial adenocarcinoma 30.1 TP53 KRT7 KRAS ERBB2 CTNNB1
28 lynch syndrome 30.0 TP53 KRAS CTNNB1 BRCA1
29 squamous cell carcinoma 30.0 TP53 MUC1 HRAS ERBB2 CTNNB1
30 ovarian cancer 29.8 TP53 MUC1 KRT7 KRAS HNF1B ERBB2
31 colon adenocarcinoma 29.7 KRT20 KRAS CTNNB1 CEACAM5 BAX
32 cervical cancer 29.7 TP53 HRAS GNAS ERBB2 CTNNB1 BAX
33 pseudomyxoma peritonei 29.7 TP53 MUC1 KRT7 KRT20 KRAS CDX2
34 renal cell carcinoma, nonpapillary 29.7 MUC1 KRT7 KRT20 HNF1B
35 endometrial cancer 29.5 TP53 KRT7 KRAS HRAS ERBB2 CTNNB1
36 carcinosarcoma 29.4 TP53 MUC1 KRT7 KRAS HRAS ERBB2
37 colorectal adenocarcinoma 29.0 TP53 KRT7 KRT20 KRAS HRAS CTNNB1
38 hepatocellular carcinoma 28.9 TP53 KRT7 KRAS HRAS GNAS CTNNB1
39 esophageal cancer 28.6 TP53 MUC1 KRAS HRAS ERBB2 CTNNB1
40 pancreatic cancer 28.4 TP53 MUC1 KRAS HRAS ERBB2 CTNNB1
41 breast cancer 28.1 TP53 MUC1 KRAS HRAS GNAS ERBB2
42 lung cancer susceptibility 3 27.8 TP53 MUC1 KRT7 KRT20 KRAS HRAS
43 colorectal cancer 27.4 TP53 MUC1 KRT7 KRT20 KRAS HRAS
44 clear cell adenocarcinoma of the ovary 12.6
45 rete ovarii adenocarcinoma 11.2
46 ovary serous adenocarcinoma 11.2
47 endometrioid ovary carcinoma 11.2
48 gastric papillary adenocarcinoma 10.8 TP53 ERBB2
49 ovary neuroendocrine neoplasm 10.8 KRT7 CDX2
50 uterine body mixed cancer 10.7 TP53 ERBB2 ARID1A

Graphical network of the top 20 diseases related to Ovary Adenocarcinoma:



Diseases related to Ovary Adenocarcinoma

Symptoms & Phenotypes for Ovary Adenocarcinoma

Human phenotypes related to Ovary Adenocarcinoma:

59 32 (show all 19)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 episodic abdominal pain 59 32 frequent (33%) Frequent (79-30%) HP:0002574
2 abdominal distention 59 32 frequent (33%) Frequent (79-30%) HP:0003270
3 nausea 59 32 frequent (33%) Frequent (79-30%) HP:0002018
4 episodic vomiting 59 32 frequent (33%) Frequent (79-30%) HP:0002572
5 endometriosis 59 32 frequent (33%) Frequent (79-30%) HP:0030127
6 elevated carcinoma antigen 125 level 59 32 frequent (33%) Frequent (79-30%) HP:0031030
7 ascites 59 32 occasional (7.5%) Occasional (29-5%) HP:0001541
8 thromboembolism 59 32 occasional (7.5%) Occasional (29-5%) HP:0001907
9 feeding difficulties 59 32 occasional (7.5%) Occasional (29-5%) HP:0011968
10 intestinal obstruction 59 32 occasional (7.5%) Occasional (29-5%) HP:0005214
11 urinary urgency 59 32 occasional (7.5%) Occasional (29-5%) HP:0000012
12 menorrhagia 59 32 occasional (7.5%) Occasional (29-5%) HP:0000132
13 dysmenorrhea 59 32 occasional (7.5%) Occasional (29-5%) HP:0100607
14 abdominal mass 59 32 occasional (7.5%) Occasional (29-5%) HP:0031500
15 pleural effusion 59 32 occasional (7.5%) Occasional (29-5%) HP:0002202
16 ovarian papillary adenocarcinoma 59 32 occasional (7.5%) Occasional (29-5%) HP:0006774
17 ovarian mucinous tumor 59 32 occasional (7.5%) Occasional (29-5%) HP:0031494
18 elevated carcinoembryonic antigen level 59 32 very rare (1%) Very rare (<4-1%) HP:0031029
19 cervical lymphadenopathy 59 32 very rare (1%) Very rare (<4-1%) HP:0025289

GenomeRNAi Phenotypes related to Ovary Adenocarcinoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability in esophageal squamous lineage GR00235-A 9.32 ARID1A BRCA1 CTNNB1 ERBB2 GNAS HNF1B

MGI Mouse Phenotypes related to Ovary Adenocarcinoma:

46 (show all 17)
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.35 ACSBG1 ARID1A BAX BRCA1 CDX2 CTNNB1
2 homeostasis/metabolism MP:0005376 10.34 ACSBG1 ARID1A BAX BRCA1 CDX2 CTNNB1
3 growth/size/body region MP:0005378 10.3 ARID1A BAX BRCA1 CDX2 CTNNB1 ERBB2
4 embryo MP:0005380 10.2 ARID1A BRCA1 CDX2 CTNNB1 ERBB2 HNF1B
5 craniofacial MP:0005382 10.17 ARID1A CTNNB1 ERBB2 GNAS HRAS INHBA
6 digestive/alimentary MP:0005381 10.16 BRCA1 CDX2 CTNNB1 ERBB2 HRAS INHBA
7 muscle MP:0005369 10.13 ARID1A BAX BRCA1 CTNNB1 ERBB2 GNAS
8 limbs/digits/tail MP:0005371 10.11 BAX BRCA1 C1RL CDX2 CTNNB1 ERBB2
9 neoplasm MP:0002006 10.1 ARID1A BAX BRCA1 CDX2 CTNNB1 ERBB2
10 integument MP:0010771 10.08 BRCA1 CTNNB1 ERBB2 GNAS HRAS INHBA
11 normal MP:0002873 10.02 ARID1A BRCA1 CDX2 CTNNB1 ERBB2 GNAS
12 hearing/vestibular/ear MP:0005377 9.99 ARID1A BAX CTNNB1 GNAS KRAS TP53
13 renal/urinary system MP:0005367 9.96 BAX BRCA1 CTNNB1 GNAS HNF1B HRAS
14 no phenotypic analysis MP:0003012 9.91 ARID1A CTNNB1 ESS2 GNAS HRAS KRAS
15 reproductive system MP:0005389 9.85 ACSBG1 ARID1A BAX BRCA1 CDX2 CTNNB1
16 respiratory system MP:0005388 9.56 BAX BRCA1 CTNNB1 ERBB2 GNAS HRAS
17 skeleton MP:0005390 9.4 ARID1A BAX BRCA1 C1RL CDX2 CTNNB1

Drugs & Therapeutics for Ovary Adenocarcinoma

Drugs for Ovary Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 39)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oxaliplatin Approved, Investigational Phase 3 61825-94-3 5310940 9887054 43805 6857599
2
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
3
Bevacizumab Approved, Investigational Phase 3 216974-75-3
4
Capecitabine Approved, Investigational Phase 3 154361-50-9 60953
5
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
6 Immunoglobulin G Phase 3
7 Antineoplastic Agents, Phytogenic Phase 3
8 Mitogens Phase 3
9 Angiogenesis Inhibitors Phase 3
10 Angiogenesis Modulating Agents Phase 3
11 Tubulin Modulators Phase 3
12 Albumin-Bound Paclitaxel Phase 3
13 Antineoplastic Agents, Immunological Phase 3
14 Antibodies Phase 3
15 Immunoglobulins Phase 3
16 Antimitotic Agents Phase 3
17 Endothelial Growth Factors Phase 3
18 Antibodies, Monoclonal Phase 3
19 Antimetabolites Phase 3
20 Antimetabolites, Antineoplastic Phase 3
21
Nintedanib Approved Phase 2 656247-17-5 56843413
22
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
23
Sargramostim Approved, Investigational Phase 2 83869-56-1, 123774-72-1
24
Aldesleukin Approved Phase 2 85898-30-2, 110942-02-4
25
Oregovomab Investigational Phase 2 213327-37-8
26 Dianhydrogalactitol Investigational Phase 1, Phase 2 23261-20-3
27 Protein Kinase Inhibitors Phase 2
28 Pharmaceutical Solutions Phase 2
29 Alkylating Agents Phase 1, Phase 2
30 Antineoplastic Agents, Alkylating Phase 1, Phase 2
31 Immunologic Factors Phase 2
32 Vaccines Phase 2
33 Adjuvants, Immunologic Phase 2
34 Freund's Adjuvant Phase 2
35 Anti-Infective Agents Phase 2
36 Anti-Retroviral Agents Phase 2
37 Anti-HIV Agents Phase 2
38 Antiviral Agents Phase 2
39
Cisplatin Approved Phase 1 15663-27-1 84093 441203 2767

Interventional clinical trials:

(show all 13)
# Name Status NCT ID Phase Drugs
1 A GCIG Intergroup Multicenter Phase III Trial of Open Label Carboplatin and Paclitaxel +/- NCI-Supplied Agent: Bevacizumab (NSC #704865) Compared With Oxaliplatin and Capecitabine +/- Bevacizumab as First Line Chemotherapy in Patients With Mucinous Epithelial Ovarian or Fallopian Tube Cancer (MEOC) Active, not recruiting NCT01081262 Phase 3 Capecitabine;Carboplatin;Oxaliplatin;Paclitaxel
2 A Randomized, Double-Blind, Placebo-Controlled, Phase IIB Study of the Safety and Efficacy of OVAREX MabB43.13 in Ovarian Cancer Patients With an Elevated Serum CA 125 But Without Other Evidence of Disease Unknown status NCT00004064 Phase 2
3 OVax®: A Feasibility Study Using a DNP-Modified Autologous Ovarian Tumor Cell Vaccine as Therapy in Ovarian Cancer Patients After Relapse: Unknown status NCT00660101 Phase 1, Phase 2
4 Randomized Double Blind Placebo-controlled Phase II Trial of Vargatef® (Nintedanib) in Addition to First Line Chemotherapy With Interval Debulking Surgery in Patients With Adenocarcinoma of the Ovary, the Fallopian Tube or Serous Adenocarcinoma of the Peritoneum Completed NCT01583322 Phase 2 vargatef;placebo
5 A Phase II, Open-Label, Non-Randomized, Multi-Center Pilot Study of Intravenous Taxol, Carboplatin, Bevacizumab Given Every 21 Days in Patients With Newly Diagnosed Stage III/IV Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer Completed NCT00127920 Phase 2 Avastin
6 Evaluation of the Efficacy of Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma Completed NCT01824615 Phase 2 Sunitinib
7 Modular Phase 2 Study to Link Combination Immune-therapy to Patients With Advanced Solid and Hematologic Malignancies. Module 9: PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies. Active, not recruiting NCT03365791 Phase 2
8 A Phase 1/2, Open Label, Multi-center Study of VAL-083 in Patients With Recurrent Platinum Resistant Ovarian Cancer Not yet recruiting NCT03281681 Phase 1, Phase 2 VAL-083, Dianhydrogalactitol
9 Vaccine Therapy With Tumor Specific p53 Peptides in Adult Patients With Low Burden Adenocarcinoma of the Ovary Terminated NCT00001827 Phase 2
10 A Phase I Study of a Tropism Modified Conditionally Replicative Adenovirus Vector (Ad5-Delta 24 RGD)for Intraperitoneal Delivery in Ovarian and Extraovarian Cancer Patients (Infectivity Enhanced Virotherapy for Ovarian Cancer) Completed NCT00562003 Phase 1 Ad5-delta24RGD
11 Phase I Study of Cisplatin Hyperthermic Intraperitoneal Chemotherapy Dose Escalation After Surgery in Patients With Unresectable Stage IIIC Ovarian, Tube or Peritoneal Primary Adenocarcinoma Previously Treated by Chemotherapy and Completed by Bevacizumab for 15 Months Completed NCT02217956 Phase 1 Cisplatin;Bevacizumab
12 A Phase 1 Study of Intraperitoneal MCY-M11 Therapy for Women With Platinum Resistant High Grade Serous Adenocarcinoma of the Ovary, Primary Peritoneum, or Fallopian Tube, or Subjects With Peritoneal Mesothelioma With Recurrence After Prior Chemotherapy Recruiting NCT03608618 Phase 1
13 The Analyses of Treatment Efficacy and Cost-effectiveness in Early-staged Ovarian Cancer Patients Treated With or Without Paclitaxel Regimens Recruiting NCT03019315

Search NIH Clinical Center for Ovary Adenocarcinoma

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Cyclophosphamide
Thiotepa

Genetic Tests for Ovary Adenocarcinoma

Anatomical Context for Ovary Adenocarcinoma

MalaCards organs/tissues related to Ovary Adenocarcinoma:

41
Ovary, Breast, Testes, Endothelial, Lymph Node, Brain, Lung

Publications for Ovary Adenocarcinoma

Articles related to Ovary Adenocarcinoma:

(show top 50) (show all 1014)
# Title Authors PMID Year
1
Interaction with Blood Proteins of a Ruthenium(II) Nitrofuryl Semicarbazone Complex: Effect on the Antitumoral Activity. 38
31394747 2019
2
Hyperthermia potentiates cisplatin cytotoxicity and negative effects on mitochondrial functions in OVCAR-3 cells. 38
31332716 2019
3
Effect of electrochemotherapy with betulinic acid or cisplatin on regulation of heat shock proteins in metastatic human carcinoma cells in vitro. 38
31002374 2019
4
Novel half-sandwich rhodium(III) and iridium(III) photosensitizers for dual chemo- and photodynamic therapy. 38
31048016 2019
5
Hepatic nontuberculous mycobacterial granulomas in patients with cancer mimicking metastases: an analysis of three cases. 38
31367567 2019
6
A Severe, Refractory Case of Mucous Membrane Pemphigoid After Treatment With Pembrolizumab: Brief Communication. 38
31246641 2019
7
Functional balance between Tcf21-Slug defines cellular plasticity and migratory modalities in high grade serous ovarian cancer cell lines. 38
31241128 2019
8
Photodynamic Therapy of Ovarian Carcinoma Cells with Curcumin-Loaded Biodegradable Polymeric Nanoparticles. 38
31208085 2019
9
Penetration Efficiency of Antitumor Agents in Ovarian Cancer Spheroids: The Case of Recombinant Targeted Toxin DARPin-LoPE and the Chemotherapy Drug, Doxorubicin. 38
31067739 2019
10
18F-FDG PET/CT of Lung Adenocarcinoma With Ovarian Metastases. 38
30789397 2019
11
Fabrication of gold-silver core-shell nanoparticles for performing as ultrabright SERS-nanotags inside human ovarian cancer cells. 38
30974419 2019
12
α-Mangostin and Apigenin Induced Cell Cycle Arrest and Programmed Cell Death in SKOV-3 Ovarian Cancer Cells. 38
31015899 2019
13
Surface-enhanced Resonance Raman Scattering Nanoprobe Ratiometry for Detecting Microscopic Ovarian Cancer via Folate Receptor Targeting. 38
30958459 2019
14
Follicle-Stimulating Hormone Is an Autocrine Regulator of the Ovarian Cancer Metastatic Niche Through Notch Signaling. 38
30680340 2019
15
IL13-Mediated Dectin-1 and Mannose Receptor Overexpression Promotes Macrophage Antitumor Activities through Recognition of Sialylated Tumor Cells. 38
30610060 2019
16
A protein nanocontainer targeting epithelial cancers: rational engineering, biochemical characterization, drug loading and cell delivery. 38
30706922 2019
17
KIFC1 regulated by miR-532-3p promotes epithelial-to-mesenchymal transition and metastasis of hepatocellular carcinoma via gankyrin/AKT signaling. 38
30115976 2019
18
Methylation of the first exon in the erythropoietin receptor gene does not correlate with its mRNA and protein level in cancer cells. 38
30606107 2019
19
Development and validation of an improved diced electrophoresis gel assay cutter-plate system for enzymomics studies. 38
29928991 2019
20
Synchronous Ovarian and Breast Cancers with a Novel Variant in BRCA2 Gene: A Case Report. 38
30723561 2019
21
Methotrexate-induced apoptosis in human ovarian adenocarcinoma SKOV-3 cells via ROS-mediated bax/bcl-2-cyt-c release cascading. 38
30588027 2019
22
Increased 131I Accumulation in the Gallbladder and High-grade Serous Ovarian Adenocarcinoma. 38
30371583 2019
23
Anti-neoplastic effect of mangiferin on human ovarian adenocarcinoma OVCAR8 cells via the regulation of YAP. 38
30655860 2019
24
Suppression of autophagy enhances preferential toxicity of epothilone A and epothilone B in ovarian cancer cells. 38
31029905 2019
25
Use of the term atypical cells in the reporting of ascitic fluid cytology: A caveat. 38
31367221 2019
26
Solid-liquid Interface Screening SystemーApplication to the Screening of Antibiotic and Cytotoxic Substance-producing Fungi. 38
30880313 2019
27
Dual functions for OVAAL in initiation of RAF/MEK/ERK prosurvival signals and evasion of p27-mediated cellular senescence. 38
30478051 2018
28
Preventative effect of celecoxib in dimethylbenz[a]anthracene-induced ovarian cancer in rats. 38
30242499 2018
29
Paraneoplastic Cerebellar Degeneration Associated With Ovarian Adenocarcinoma: A Case Report and Review of Literature. 38
30532364 2018
30
Tumor is an Oxidative Stress Factor in Ovarian Cancer Patients. 38
30383995 2018
31
Core-shell poly-methyl methacrylate nanoparticles covalently functionalized with a non-symmetric porphyrin for anticancer photodynamic therapy. 38
30064063 2018
32
An Ovarian Adenocarcinoma With Combined Low-grade Serous and Mesonephric Morphologies Suggests a Müllerian Origin for Some Mesonephric Carcinomas. 38
28863071 2018
33
Redox-Dependent Expression of Genes Encoding NADPH Oxidase 5 and the Key Antioxidant Enzymes during Formation of Drug Resistance of Tumor Cells to Cisplatin. 38
30225719 2018
34
In-vitro antitumor activity of new quaternary phosphonium salts, derivatives of 3-hydroxypyridine. 38
29738336 2018
35
Low Dose of Bisphenol A Modulates Ovarian Cancer Gene Expression Profile and Promotes Epithelial to Mesenchymal Transition Via Canonical Wnt Pathway. 38
29718440 2018
36
Blockade of ONECUT2 expression in ovarian cancer inhibited tumor cell proliferation, migration, invasion and angiogenesis. 38
29737581 2018
37
Design, Synthesis, and Evaluation of Homochiral Peptides Containing Arginine and Histidine as Molecular Transporters. 38
29966296 2018
38
Effect of combined inhibition of p110 alpha PI3K isoform and STAT3 pathway in ovarian cancer platinum-based resistance. 38
29930760 2018
39
Sphincter-preserving surgery for recurrent pelvic malignancy using a hybrid procedure of open laparotomy and transanal endoscopic approach. 38
29651788 2018
40
Metformin and epothilone A treatment up regulate pro-apoptotic PARP-1, Casp-3 and H2AX genes and decrease of AKT kinase level to control cell death of human hepatocellular carcinoma and ovary adenocarcinoma cells. 38
29117515 2018
41
GADD45β Loss Ablates Innate Immunosuppression in Cancer. 38
29279355 2018
42
Antitumor activity of pyrrolizines and their Cu(II) complexes: Design, synthesis and cytotoxic screening with potential apoptosis-inducing activity. 38
29335201 2018
43
Targeting EGFR and uPAR on human rhabdomyosarcoma, osteosarcoma, and ovarian adenocarcinoma with a bispecific ligand-directed toxin. 38
30288129 2018
44
Human cytomegalovirus in high grade serous ovarian cancer possible implications for patients survival. 38
29369188 2018
45
Survival rates among women with ovarian cancers diagnosed in the area of Podkarpacie province in the years 1990-2015. 38
30455586 2018
46
Primary T cells for mRNA-mediated immunotoxin delivery. 38
28937681 2018
47
False Positive 18F-FDG Positron Emission Tomography Findings in Schwannoma-A Caution for Reporting Physicians. 38
30349818 2018
48
Novel Symmetrical 1,4-Disubstituted-bis-1,2,3-Triazoles: Synthesis by Double CuAAC and Cytotoxicity Evaluation. 38
30345921 2018
49
Successful Pregnancy Outcome in Recurrent Ovarian Cancer in a 26 Year Old: A Case Report. 38
30288170 2017
50
Probable paclitaxel-induced pancreatitis: uncommon case report and literature review. 38
29299374 2017

Variations for Ovary Adenocarcinoma

ClinVar genetic disease variations for Ovary Adenocarcinoma:

6
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 ERBB2 NM_004448.3(ERBB2): c.2570A> G (p.Asn857Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28933370 17:37881378-37881378 17:39725125-39725125

Copy number variations for Ovary Adenocarcinoma from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 118124 17 7571720 7590868 Mutation TP53 Ovarian adenocarcinomas

Expression for Ovary Adenocarcinoma

Search GEO for disease gene expression data for Ovary Adenocarcinoma.

Pathways for Ovary Adenocarcinoma

Pathways related to Ovary Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 45)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.84 TP53 MUC1 KRAS HRAS HNF1B GNAS
2
Show member pathways
13.52 TP53 KRAS HRAS HNF1B GNAS ERBB2
3
Show member pathways
12.99 TP53 KRAS HRAS GNAS CTNNB1 CDX2
4
Show member pathways
12.94 TP53 KRAS HRAS GNAS CTNNB1 BAX
5
Show member pathways
12.84 TP53 KRAS HRAS ERBB2 CTNNB1 BAX
6
Show member pathways
12.76 TP53 KRAS HRAS GNAS ERBB2 CTNNB1
7 12.7 TP53 KRAS HRAS GNAS ERBB2 CTNNB1
8
Show member pathways
12.67 TP53 KRAS HRAS ERBB2 CTNNB1 BAX
9
Show member pathways
12.54 TP53 KRAS HRAS GNAS ERBB2 BRCA1
10 12.5 TP53 KRAS HRAS ERBB2 BRCA1
11
Show member pathways
12.5 TP53 KRAS HRAS ERBB2 CTNNB1 BAX
12
Show member pathways
12.37 KRAS HRAS CTNNB1 BRCA1
13 12.31 TP53 KRAS HRAS CTNNB1 BAX
14 12.27 TP53 KRAS HRAS BAX
15 12.27 TP53 KRAS HRAS ERBB2 CTNNB1
16
Show member pathways
12.27 TP53 KRAS HRAS ERBB2 CTNNB1 BAX
17
Show member pathways
12.17 TP53 KRAS HRAS ERBB2 BAX
18
Show member pathways
12.12 TP53 KRAS HRAS BAX
19
Show member pathways
12.11 TP53 KRAS HRAS BAX
20
Show member pathways
12.11 KRAS HRAS GNAS ERBB2
21 12.09 TP53 KRAS GNAS CTNNB1 BAX
22 12.08 TP53 KRAS HRAS ERBB2 BAX
23 12.07 KRAS INHBA HRAS CTNNB1
24 12.04 TP53 KRAS CTNNB1 BRCA1 BAX
25 11.98 TP53 KRAS HRAS BAX
26 11.98 TP53 KRAS HRAS CTNNB1
27 11.94 TP53 KRAS HRAS CTNNB1
28
Show member pathways
11.94 TP53 KRAS HRAS ERBB2 CTNNB1 CDX2
29 11.81 KRAS HRAS GNAS
30
Show member pathways
11.78 KRAS HRAS BAX
31 11.71 TP53 ERBB2 BRCA1 BAX
32 11.7 TP53 KRAS HRAS ERBB2
33 11.66 TP53 KRAS HRAS
34 11.65 TP53 KRAS HRAS ERBB2
35 11.61 KRAS HRAS GNAS
36 11.59 INHBA HRAS CTNNB1
37 11.58 KRAS HRAS ERBB2
38 11.55 TP53 KRAS HRAS BRCA1
39 11.49 TP53 KRAS HRAS ERBB2 CTNNB1 BAX
40 11.48 TP53 BRCA1 BAX
41 11.37 KRAS HRAS GNAS ERBB2
42 11.37 TP53 HRAS ERBB2 BRCA1 ARID1A
43 11.29 TP53 KRAS HRAS
44 11.03 KRAS HRAS ERBB2 CTNNB1
45 10.81 KRAS HRAS

GO Terms for Ovary Adenocarcinoma

Cellular components related to Ovary Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.47 TP53 SERPINA3 MUC1 KRT7 HRAS HNF1B

Biological processes related to Ovary Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 apoptotic process GO:0006915 9.97 TP53 KRT20 HRAS CEACAM5 BRCA1 BAX
2 negative regulation of cell proliferation GO:0008285 9.96 TP53 INHBA HRAS CTNNB1 BAX
3 nervous system development GO:0007399 9.8 INHBA ESS2 ERBB2 CTNNB1 BAX ARID1A
4 Ras protein signal transduction GO:0007265 9.74 TP53 KRAS HRAS
5 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.72 MUC1 KRAS HRAS
6 positive regulation of MAP kinase activity GO:0043406 9.71 KRAS HRAS ERBB2
7 positive regulation of transcription, DNA-templated GO:0045893 9.7 TP53 INHBA HNF1B CTNNB1 CDX2 BRCA1
8 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 9.69 TP53 MUC1 BAX
9 cell proliferation GO:0008283 9.65 TP53 CTNNB1 BAX
10 regulation of apoptotic process GO:0042981 9.65 TP53 INHBA CTNNB1 BRCA1 BAX
11 chromatin-mediated maintenance of transcription GO:0048096 9.58 CTNNB1 ARID1A
12 androgen receptor signaling pathway GO:0030521 9.58 CTNNB1 BRCA1 ARID1A
13 intrinsic apoptotic signaling pathway GO:0097193 9.54 TP53 HRAS BAX
14 response to isolation stress GO:0035900 9.52 KRAS HRAS
15 hair follicle placode formation GO:0060789 9.46 GNAS CTNNB1
16 cellular response to indole-3-methanol GO:0071681 9.43 CTNNB1 BRCA1
17 positive regulation of gene expression GO:0010628 9.23 TP53 KRAS INHBA HRAS HNF1B ERBB2
18 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.13 TP53 MUC1 BRCA1
19 regulation of transcription by RNA polymerase II GO:0006357 10.13 INHBA HNF1B ERBB2 CTNNB1 CDX2 BRCA1

Molecular functions related to Ovary Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein phosphatase binding GO:0019903 9.13 TP53 ERBB2 CTNNB1
2 protein heterodimerization activity GO:0046982 9.1 TP53 INHBA HNF1B ERBB2 CTNNB1 BAX

Sources for Ovary Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....